If you are a non-UPMC provider and would like to order the Monoclonal Antibody administration for a patient under your care, please:
NOTE: UPMC will no longer accept any prior referral sources.
Eligible patients are typically contacted within 24 to 48 hours if an appointment time is available.
If you are a patient and want information about Monoclonal Antibody treatment, call 866-804-5251.
UPMC is one of the few health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.
This one-time administration may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.
UPMC is using a monoclonal antibody administration treatment product in outpatient infusion center locations throughout western, central, and north central PA. The product is:
Fact Sheet for Health Care Providers: EUA for Bebtelovimab (fda.gov)
Fact Sheet for Patients, Parents, and Caregivers: EUA of Bebtelovimab for Coronavirus Disease 2019 (COVID-19) (fda.gov)
UPMC can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment.
Eligibility criteria are currently prioritized for the following patients:
Not authorized for use in patients:
Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.
With many medications, there is a risk of allergic reaction, albeit reactions to these medications requiring discontinuation are very rare. The infusion centers have trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.
Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after the vaccination, if the person is eligible to receive monoclonal antibody.
Persons who received monoclonal antibodies for treatment of COVID-19 can receive a COVID-19 vaccine as soon as they are clinically well (recovered) and considered no longer contagious.
Check out our web page for information for patients about Paxlovid™ and monoclonal antibody treatment.
Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals.Learn more about this medication.